Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.48 |
| ▸ | CDK2 | P24941 | 3/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 5/20 | 0.43 |
| ▸ | JAK1 | P23458 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 3/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | BRD2 | P25440 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.42 |
| ▸ | STK4 | Q13043 | 3/20 | 0.42 |
| ▸ | TYK2 | P29597 | 2/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633194 | 1.00 | CDK1 (0.48) | CDK1CDK2CDK9SYKJAK2 | |
| SCHEMBL1632614 | 1.00 | CDK1 (0.48) | CDK1CDK2CDK9SYKJAK2 | |
| SCHEMBL1631212 | 0.85 | MAPK10 (0.47) | CDK1CDK2CDK9JAK2JAK1 | |
| SCHEMBL1632234 | 0.85 | MAPK10 (0.47) | CDK1CDK2CDK9JAK2JAK1 | |
| SCHEMBL1631208 | 0.85 | MAPK10 (0.47) | CDK1CDK2CDK9JAK2JAK1 | |
| SCHEMBL1632748 | 0.83 | MTOR (0.58) | CDK1CDK2CDK9SYKJAK2 | |
| SCHEMBL1633920 | 0.83 | MTOR (0.49) | CDK1CDK2CDK9SYKJAK2 | |
| SCHEMBL1634662 | 0.81 | MAPK10 (0.56) | SYKJAK2JAK3MTORSMG1 | |
| SCHEMBL12724211 | 0.80 | MTOR (0.48) | CDK1CDK2CDK9SYKJAK2 | |
| SCHEMBL1633514 | 0.80 | CDK1 (0.44) | CDK1CDK2CDK9JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | CDK1 83/4885CDK2 29/4885CDK9 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.